Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

7.790 -0.010 (-0.13%)
Official Closing Price Updated: 4:15 PM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
23 24 Next >
News headline image
Why ImmunityBio Stock Is Skyrocketing Again Today ↗
It has been an incredible week of positive news for ImmunityBio. 
Via The Motley Fool
Curious about the most active stocks on Friday? ↗
Via Chartmill
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today ↗
Via Stocktwits
IBRX Stock Continues Rally — What’s Driving The Optimism Today? ↗
Via Stocktwits
IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval ↗
Via Stocktwits
IBRX Garners Retail Attention On Positive Update In Immunotherapy For Lung Cancer Patients ↗
Via Stocktwits
News headline image
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
From ImmunityBio, Inc.
Via Business Wire
News headline image
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700% ↗
On Jan. 15, 2026, investors took note of Anktiva's explosive sales ramp, its geographic expansion potential, and a possible new indication. 
Via The Motley Fool
Topics Earnings Stocks
Thursday's session: top gainers and losers ↗
Via Chartmill
Which stocks are moving on Thursday? ↗
Via Chartmill
News headline image
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
From ImmunityBio, Inc.
Via Business Wire
News headline image
MAGA SmallCaps Watchlist: ROLR, SURG, IBRX, BNAI, NDRA – January 2026 Focus
Via AB Newswire
Topics Derivatives
News headline image
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
Issued on behalf of Oncolytics Biotech Inc. 
From USA News Group
Via GlobeNewswire
News headline image
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
From ImmunityBio
Via Business Wire
News headline image
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer
From ImmunityBio, Inc.
Via Business Wire
News headline image
NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”
From ImmunityBio, Inc.
Via Business Wire
News headline image
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe
From ImmunityBio
Via Business Wire
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know ↗
A major fund just opened a multimillion-dollar position in ImmunityBio—and the move could hint at rising confidence in this clinical-stage immunotherapy pipeline. 
Via The Motley Fool
News headline image
Heights Capital Walks From Archer Aviation: What It Means for Investors ↗
One major investor just walked away from Archer Aviation. Here’s what that move does—and doesn’t—signal for the future of urban air mobility. 
Via The Motley Fool
News headline image
Heights Capital Just Ditched Its $12.5 Million AMSC Stake. Here’s What That Might Mean. ↗
One fund just walked away from American Superconductor—but the company’s role in the future of grid resiliency might be more important than any single quarterly filing suggests. 
Via The Motley Fool
News headline image
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
From ImmunityBio, Inc.
Via Business Wire
News headline image
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
From ImmunityBio, Inc.
Via Business Wire
News headline image
Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks ↗
Here's a look at the most heavily shorted stocks in the market as investors look for the next Beyond Meat. 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.